UK-based pharmaceutical company GSK has reported updated results from a Phase II study of Jemperli (dostarlimab) for locally advanced mismatch repair deficient (dMMR) rectal cancer.
The drug candidate was found to be 100% effective in treating all patients who were enrolled in the trial.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,